Bevacizumab combinations in 1L MBC
Cortes et al ann Oncol 2012; Manso et al Curr Oncol 2015; Smith et al Ann Oncol 2011
•
Metanalysis (5 RCTs)
•
Similar to the ATHENA study (broad community-based population)
•
LVD, hypertension, proteinuria and bleeding were more frequently observed with bevacizumab
OR = 27.68
OR = 12.76
OR = 2.25
OR = 4.07
Safety profile
AEs of special interest regardless of relationship to
treatment
